Which means that based upon only the existing and committed sum of money in CEL-SCI today, not taking into consideration management’s capability to raise extra capital, until December 2012 the accountants cannot be sure that CEL-SCI will have enough cash to continue its operations. As is actually explained in the Company’s annual record filing, CEL-SCI’s management is aware of this, likely to receive this and provides plans in place. The last period CEL-SCI received this explanatory paragraph was in January 2009. During 2009 CEL-SCI raised in excess of $40 million in collateral capital. Geert Kersten, CEO said, ‘Our Stage III scientific trial for our investigational tumor drug Multikine is enrolling sufferers on 3 continents. We intend to further expand this study in 2012 since we are pleased with its progress so far.’..These outcomes also showed that rosuvastatin 20 mg reduced the combined risk of heart attack, stroke or CV loss of life by nearly half . Related StoriesDiscovery can offer clues to how some viruses control expression of genetic materialSt. Michael's Hospital research finds that cholesterol-reducing diet also lowers blood pressureDisclosing genetic risk for CHD outcomes in decrease low-density lipoprotein cholesterolJUPITER was a long-term, randomized, double-blind, placebo-controlled, large-scale study of 17,802 patients designed to determine if rosuvastatin 20 mg decreases the risk of coronary attack, stroke and other major cardiovascular events in patients with low to normal LDL-C but at increased cardiovascular risk as identified by age and elevated high-sensitivity C-reactive protein .